Federal award (DEFINITIVE CONTRACT, fiscal year 2022)
Recipient: CELLPHIRE, INC.
Awarding agency: Department of Defense / Department of the Army
Funding agency: Department of Defense / Department of the Army
Period of performance: 2019-12-20 to 2025-12-31
Current total value of award: $24379913
Description: PHASE II CLINICAL TRIAL INCREMENTAL FUND CLIN 0001 PER SECTION 711 OF THE 2019 NDAA, USAMRAA TRANSFERRED TO DHA 10/1/2022.